This is a routine, small-dollar insider sale by a director under a 10b5-1 plan. No material signal for the stock. Monitor for any acceleration of insider selling or changes in the 10b5-1 plan, but this filing alone does not warrant a trading response.
CGON drugs
CGON drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 25 $72.84entry
- T+1 · 5mo ago −1.21%α −0.48% · $71.96
- T+5 · 5mo ago −2.68%α −4.24% · $70.89
- T+20 · 4mo ago −2.36%α −2.89% · $71.12
- T+60 · 8w ago +2.44%α −1.29% · $74.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Leonard Post filed a Form 144 notice of intent to sell 5,000 shares of CG Oncology common stock, with an estimated aggregate market value of $328,650. The shares are to be acquired through the exercise of stock options, and the sale is planned under a Rule 10b5-1 trading plan. This is a routine insider sale by a director, not a top executive, and the dollar amount is small relative to the company's $6.1B market cap.
Key Facts
- Director Leonard Post filed Form 144 on June 24, 2026, indicating intent to sell 5,000 shares.
- Estimated aggregate market value of the proposed sale is $328,650.
- Shares are to be acquired upon exercise of stock options; sale is part of a pre-arranged 10b5-1 plan.
- The sale represents a tiny fraction of the company's $6.1B market cap.
- Prior 30-day insider activity includes 3 sells totaling $419K, consistent with routine option exercise/sale patterns.
Financial Impact
Proposed sale of 5,000 shares valued at ~$328,650, representing less than 0.01% of market cap.
Risk Factors
- Insider selling could accelerate if the 10b5-1 plan is expanded or if other insiders follow suit.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006467 |
| Document: 0001950047-26-006467-index.html | 0001950047-26-006467 |
| Document: 0001950047-26-006467.txt | 0001950047-26-006467 |
Track record
25 reports on CGON
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers